Meta AnalysisID 2952

乳三肽异亮氨酸-脯氨酸-脯氨酸和缬氨酸-脯氨酸-脯氨酸对亚洲人群血压的影响:随机对照试验的系统评价与Meta分析(更新)

CRD42014014322

Do the lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline reduce systolic blood pressure in Asian subjects ? What is the influence of the ingested dose of the lactotripeptides Isoleucine–Proline–Proli

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final meta_analysis record.

Meta Analysis Id
2952
Evidence Id
11510
Core Evidence Id
11510
Source Meta Analysis Id
2902
Herb2 Meta Analysis Id
HBMA002902
Crd Id
CRD42014014322
Title
Influence of the lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-Proline on blood pressure in Asian subjects: a systematic review and meta-analysis of randomized controlled trials (update)<br />
Review Question
Do the lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline reduce systolic blood pressure in Asian subjects ? What is the influence of the ingested dose of the lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline on the effect on blood pressure?
Study Type Included
Inclusion criteria: randomized controlled trials, single blinded or double blinded, involving the consumption of Isoleucine–Proline–Proline (IPP) and Valine–Proline–Proline (VPP) by Asian adult subjects for longer than 8 days, with office systolic blood pressure measurements at baseline and one/more time points.Exclusion criteria: reviews (general or systematic reviews, meta-analyses), letters, opinion papers, view points, etc…, non-human studies, studies which are not intervention trials, intervention trials which are not randomized-controlled trials, randomized-controlled trials with an open design, studies in which no measure of SBP was reported, studies in which there was no intervention with IPP+VPP (studies testing IPP alone or VPP alone will be excluded), studies where IPP/VPP intake period is less than 8 days
Condition Being Studied
Hypertension is a major determinant of health and is likely to have an effect on medical economics worldwide, including in Japan (Nakamura et al 2014). Hypertension can be prevented with lifestyle measures, such as physical activity, maintaining a normal body weight, and adopting a healthy diet. Besides this, several randomized trials and meta-analyses have shown that some peptides derived from milk proteins, such as isoleucine–proline–proline (IPP) and valine–proline–proline (VPP), decrease systolic blood pressure (SBP). However, the size of the effect varies among studies, and it seems to be stronger in Asian subjects than in European subjects (Cicero et al 2011). Several randomized trials have been performed in Japanese subjects. No sufficient meta-analysis has been performed to specifically assess the size of the effect in Asian subjects, especially in Japanese subjects, because many studies have been written in Japanese language and because the literature has not been searched for publications in Japanese language.
Participant
Inclusion: Asian adults (subjects older than 20 yo). Exclusion: studies in diseased subjects, studies in hypertensive patients receiving blood pressure lowering drugs, studies in children (younger than 20 yo)
Animal
Human Disease Modelled
Intervention
Intervention to be reviewed will be consumption of the lactotripeptides Isoleucine–Proline–Proline (IPP) and Valine–Proline–Proline (VPP) during more than 8 days
Comparator Control
Comparison will be made with placebo
Main Outcome
Change from baseline to endpoint in systolic blood pressure.
Outcome Measure
Additional Outcome
Change from baseline to endpoint in diastolic blood pressure.
Study Method
Meta-analysis, Systematic review
Keyword
Asian Continental Ancestry Group; Blood Pressure; Humans; Oligopeptides
Contact
Dr Chanson-Rolle [email protected]
Organisational Affiliation
Funding Source
The review was initially sponsored by Calpis Co., Ltd. (11-10, 5-chome, Fuchinobe, Chuo-ku, Sagamihara-shi, Kanagawa 252-0206, Japan). Since Calpis has been acquired by Asahi Group Holdings, Ltd, the review is now sponsored by Asahi Group Holdings, Ltd (23-1, Azumabashi, 1-chome, Sumida-ku, Tokyo 130-8602, Japan).
Other Selection Criteria
Final Publication
http://journals.plos.org/plosone/article?id&amp;#61;10.1371/journal.pone.0142235
Same Topic Review
This systematic review is an update of the systematic review which was published on the PROSPERO register under the following title “Influence of the lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-Proline on blood pressure in Asian subjects: a systematic review and meta-analysis of randomized controlled trials” and under registration number CRD42014014322.
Published Protocol
Review Type
Language
English, Japanese
Country
France, Japan
Review Stage
Review Ongoing
First Submission Date
2018-07-05
Registration Date
2014-10-17
Anticipated Start Date
2014-09-11
Anticipated Completion Date
2018-08-31
Title Cn
乳三肽异亮氨酸-脯氨酸-脯氨酸和缬氨酸-脯氨酸-脯氨酸对亚洲人群血压的影响:随机对照试验的系统评价与Meta分析(更新)
Title En
Influence of the lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-Proline on blood pressure in Asian subjects: a systematic review and meta-analysis of randomized controlled trials (update)<br />
Bilingual Status
complete